Therapy of psoriasis with narrowband ultraviolet-B light influences plasma concentrations of MMP-2 and TIMP-2 in patients

Figures & data

Table 1 Characteristics of psoriatic patients and control group

Study group	Number of patients
Psoriasis patients
Plaque type	49 (23 females, 26 males)
Median age (range)	39 (18–76)
Severity
Mild	34
PASI <5	15
PASI 5–10	19
Medium	15
PASI 10–30	15
Control group
Healthy subjects	40 (19 females, 21 males)
Median age (range)	36 (18–75)

Abbreviation: PASI, Psoriasis Area and Severity Index.

Table 2 Plasma levels of the tested parameter in psoriatic patients and in control group

Groups tested	MMP-2 (ng/mL)		TIMP-2 (ng/mL)
	Before treatment	After the treatment	Before treatment	After the treatment
Psoriatic patients
Total psoriatic group	aP=0.000075 dP=0.01125
Median	185.52	176.94	81.83	80.95
Mean	213.86	189.56	86.77	85.65
Range	122.75–458.06	109.10–330.13	51.37–169.32	44.36–182.03
Mild	bP=0.000754	bP=0.021454	bP=0.018598
Median	171.23	168.58	75.06	77.04
Mean	188.72	173.88	81.50	84.51
Range	122.75–398.72	109.10–330.13	51.37–134.64	44.36–182.03
Mild – subgroup Ia	cP=0.000397	cP=0.008131	cP=0.004204
Median	142.05	144.09	72.72	73.07
Mean	165.77	153.46	75.02	89.48
Range	122.75–347.37	109.10–270.98	51.37–117.77	48.52–165.45
Mild – subgroup Ib
Median	183.59	176.94	78.94	78.01
Mean	206.84	190.01	86.62	80.59
Range	165.31–398.72	115.80–330.13	53.03–134.64	44.36–182.03
Medium	aP=0.000005 dP=0.010594	aP=0.001811	aP=0.02378 dP=0.026757
Median	246.72	237.35	93.16	89.23
Mean	270.84	225.09	98.71	88.22
Range	176.78–458.06	119.83–290.16	66.26–169.32	60.52–150.30
Control group
Healthy subjects
Median	181.45		80.44
Mean	160.44		77.87
Range	32.50–270.40		42.50–105.00

Notes:

a Statistically significant when psoriatic patients are compared with healthy subjects (P<0.05);

b statistically significant when patients with mild scales are compared to subjects with medium lesions (P<0.05);

c statistically significant when subgroup Ia is compared to medium cases (P<0.05);

d statistically significant when pretreatment concentration is compared to posttreatment levels (P<0.05).

Abbreviations: MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinases.

Figure 1 Correlation of baseline plasma metalloproteinase-2 (MMP-2) with baseline plasma tissue inhibitor of metalloproteinases-2 (TIMP-2) in patients with psoriasis.

Figure 2 Correlation of baseline plasma metalloproteinase-2 (MMP-2) with baseline Psoriasis Area and Severity Index (PASI) in patients with psoriasis.

Figure 3 Correlation of baseline plasma tissue inhibitor of metalloproteinases-2 (TIMP-2) with baseline Psoriasis Area and Severity Index (PASI) in patients with psoriasis.